Liquidia Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Liquidia (LQDA) was found to have infringed on United Therapeutics' (UTHR) patents for its drug Yutrepia, which treats high blood pressure in the lungs. The ruling caused the stocks to diverge, as UTHR's Tyvaso is a direct competitor to Yutrepia. The companies have been in a legal battle for years.
Rogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.
Liquidia Corp. (LQDA) fell 25% after a court ruling denied its motion in a patent dispute with United Therapeutics (UTHR), which rose 6.2%. The case involves Liquidia's Yutrepia drug.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning LQDA (Liquidia Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 6 bearish.
Recent LQDA coverage spans insider activity, regulation and market movers.
In the last 30 days, LQDA insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($1.2M). The most active reporter was SINGH RAMAN with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.
Liquidia likely to fall due to the adverse patent infringement ruling.
Significant downside pressure as the infringement ruling likely hampers Liquidia's pipeline and valuation.
The court ruling is a negative catalyst, likely keeping pressure on the stock.
The insider sale may signal reduced confidence, likely exerting slight downward pressure on LQDA.
Potential increase in share supply could modestly pressure price; insider sale signals limited confidence.
AlphAI scores every news story that mentions LQDA with an AI model for sentiment and relevance, and aggregates insider trades from Liquidia Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Liquidia (LQDA) was found to have infringed on United Therapeutics' (UTHR) patents for its drug Yutrepia, which treats high blood pressure in the lungs. The ruling caused the stocks to diverge, as UTHR's Tyvaso is a direct competitor to Yutrepia. The companies have been in a legal battle for years.
1 min readRogers rose 10% on higher earnings guidance ($3.80 vs. $3.65 consensus). Liquidia fell 25% after a patent infringement ruling, while United Therapeutics gained 15%. Jabil dropped 7% despite beating earnings and revenue estimates. Concentrix climbed 5% on strong earnings but issued weak guidance. Moderna fell 7% after a Citi downgrade. FormFactor gained 8% on a Deutsche Bank buy rating. Cal-Maine Foods declined 2% on a wider-than-expected loss.
2 min readLiquidia Corp. (LQDA) fell 25% after a court ruling denied its motion in a patent dispute with United Therapeutics (UTHR), which rose 6.2%. The case involves Liquidia's Yutrepia drug.
1 min readSINGH RAMAN sold 17,492 shares of Liquidia Corp (LQDA) at an average of $67.43 ($66.16–$68.62, $1.18M total) across 2 trades over 2026-09-11 to 2026-09-14.
1 min readLiquidia Corp (LQDA) director Ramandeep Singh filed a Rule 144 notice for the potential sale of 9,024 shares, valued at $619,209.73, with a proposed sale date of September 11, 2026. The shares are tied to a stock option exercise for cash.
1 min readLiquidia (LQDA) received FDA Fast Track designation for YUTREPIA, a treatment for Raynaud's phenomenon in systemic sclerosis. The company plans a Phase 2a trial in 2026. LQDA stock closed at $69.68, up 4.14%, and is up 1.18% in pre-market trading.
2 min readLiquidia Corporation (LQDA) is relying on Yutrepia, its inhaled dry-powder treprostinil therapy, to drive growth despite intense competition in the PAH market. Yutrepia generated $300.3M in sales in H1 2026 and has seen strong adoption. LQDA faces competition from United Therapeutics (UTHR) and Insmed (INSM), with UTHR expanding its PAH franchise. LQDA's shares have surged 96.3% YTD, trading at 6.16X forward sales. Analysts have lowered EPS estimates for 2026 and 2027.
2 min readAdair Jason (Chief Business Officer) sold 73,631 shares of Liquidia Corp (LQDA) at $69.09 ($5.09M total) across 2 trades on 2026-08-21 under a Rule 10b5-1 trading plan.
1 min readRielly-Gauvin Katherine sold 55,182 shares of Liquidia Corp (LQDA) at an average of $74.07 ($72.23–$74.99, $4.09M total) across 2 trades over 2026-08-19 to 2026-08-20 under a Rule 10b5-1 trading plan.
1 min readSaggar Rajeev (Chief Medical Officer) sold 79,534 shares of Liquidia Corp (LQDA) at an average of $75.09 ($74.06–$76.84, $5.97M total) across 2 trades over 2026-08-17 to 2026-08-19.
1 min read
